Laboratorios LETI

In 1919 Dr. Pedro Domingo Sanjuán, Professor of Microbiology at the Universidad Autonoma de Barcelona, Spain and researcher at the Municipal Laboratory of Barcelona, Spain founded the Laboratorio Experimental de Terapéutica Inmunógena (LETI) for the development and production of vaccines.

The LETI Group Immunology and Vaccines Business Unit's mission is to ameliorate suffering and to provide hope to millions of people affected by rare or neglected diseases in all parts of the world. Our goal is to develop effective vaccines and therapies that will allow us to fulfill our mission.

In the process of developing vaccines and therapeutics, we aim to work hand-in-hand with researchers and clinicians to further the scientific and clinical understanding of the diseases we study.

Today, Laboratorios LETI is positioned as one of the leading companies in the area of leishmaniasis research. With over twenty years of experience, and several antigens and adjuvants in our pipeline, our goal is to deliver several much needed vaccine and diagnostic candidates to clinic, and ultimately to market.

Our commitment to the development of vaccines for human and canine leishmaniasis stems from an awareness of the tremendous unmet need for solutions for this life-threatening and disabling condition.

We currently have nine research projects and three clinical candidates in our portfolio. Our patents extend beyond leishmaniasis and into other protozoan infections.